Le infezioni delle vie urinarie (IVU) colpiscono oltre 150 milioni di persone in tutto il mondo ogni anno, rendendole una delle infezioni batteriche più comuni nella pratica clinica. Vanno dalle IVU basse non complicate (cistite) in donne altrimenti sane, alle gravi infezioni delle vie urinarie alte (pielonefrite) e alle infezioni associate a catetere che richiedono l'ospedalizzazione. Questa guida copre lo spettro clinico delle IVU — tra cui cause, diagnosi, protocolli di trattamento antibiotico e prevenzione — con indicazioni cliniche basate sulle linee guida EAU e IDSA.
What is a Urinary Tract Infection?
A urinary tract infection (UTI) is an infection that affects any part of the urinary system — including the kidneys, ureters, bladder, and urethra. Most infections involve the lower urinary tract, primarily the bladder and the urethra.
UTIs are among the most common bacterial infections in the world. While they can affect anyone, women are significantly more susceptible due to their shorter urethra, which allows bacteria to reach the bladder more easily.
When to see a doctor
If you experience burning urination, pelvic pain, cloudy urine, or a persistent urge to urinate, consult a healthcare professional. Untreated UTIs can spread to the kidneys.
Urinary tract infections represent a spectrum of conditions ranging from uncomplicated cystitis in healthy premenopausal women to complex urosepsis in catheterized, immunocompromised, or structurally abnormal patients. Classification is critical for guiding empirical therapy.
| Classification | Definition | Key Considerations |
|---|---|---|
| Uncomplicated UTI | Lower UTI in non-pregnant women without structural/functional abnormalities | Short-course antibiotics; no imaging required |
| Complicated UTI | Any UTI associated with functional/structural urinary tract abnormality, or in special populations (men, pregnant women, immunocompromised, catheterized patients) | Urine culture mandatory; longer treatment course |
| Recurrent UTI | ≥3 episodes per year or ≥2 episodes in 6 months | Investigate underlying cause; consider prophylaxis |
| Catheter-associated UTI (CAUTI) | UTI in patients with urinary catheter in place for >2 days | Remove catheter if possible; distinct antibiogram |
| Asymptomatic Bacteriuria | ≥10⁵ CFU/mL on 2 consecutive specimens without symptoms | Treatment only in pregnancy and pre-urological procedures |
Anatomy of the Urinary Tract
Kidneys
Filter blood, produce urine. Kidney infections (pyelonephritis) are serious and require prompt treatment.
Ureters
Tubes carrying urine from kidneys to bladder. Can be affected by stones or strictures.
Bladder
Stores urine. Cystitis (bladder infection) is the most common UTI form.
Urethra
Carries urine outside the body. Urethritis often presents with discharge and burning.
Clinical Note — Ascending Infection Pathway
The most common route of infection is ascending, with periurethral colonization by uropathogens (predominantly E. coli expressing type 1 and P fimbriae) followed by bladder invasion. Vesico-ureteral reflux (VUR), bladder outlet obstruction, ureteral stenting, and nephrostomy access all create conditions that promote retrograde ascent into the upper urinary tract. The female urethra (3–4 cm) versus the male (20 cm) accounts for the marked sex disparity in uncomplicated UTI incidence.
Causes & Risk Factors
UTIs are most commonly caused by bacteria from the gut, particularly Escherichia coli (E. coli), which accounts for around 80–85% of cases. These bacteria can enter the urinary tract and multiply rapidly.
| Pathogen | Frequency | Key Notes |
|---|---|---|
| Escherichia coli | 80–85% | Virulence factors: fimbriae, hemolysin, cytotoxic necrotizing factor |
| Staphylococcus saprophyticus | 5–15% (young women) | Novobiocin-resistant; seasonal peaks in summer/autumn |
| Klebsiella pneumoniae | 5–8% | Emerging ESBL producers; nosocomial setting |
| Proteus mirabilis | 2–5% | Urease-producer; associated with struvite stones |
| Pseudomonas aeruginosa | <3% | Predominantly nosocomial/catheter-associated; high resistance rates |
| Enterococcus faecalis | <5% | Post-urological procedure; consider VRE in hospital settings |
Risk Factors
Signs & Symptoms
Lower UTI (Cystitis / Urethritis)
- Burning or painful urination (dysuria)
- Frequent, urgent need to urinate
- Passing only small amounts of urine
- Cloudy, dark, or strong-smelling urine
- Blood in urine (haematuria)
- Pelvic pressure or discomfort
Upper UTI (Pyelonephritis) ⚠️
- Fever and chills
- Flank, back, or side pain
- Nausea and vomiting
- High temperature (>38°C / 100.4°F)
- Costovertebral angle tenderness
- Requires immediate medical care
Clinical Pearl — Atypical Presentations
Elderly patients (especially those with dementia or delirium) and immunocompromised individuals frequently lack classic dysuria/frequency, presenting instead with unexplained delirium, falls, or haemodynamic instability. Catheterized patients may be asymptomatic or present only with suprapubic discomfort. Overdiagnosis of UTI in the elderly (attributing delirium to UTI without meeting formal NHSN/IDSA criteria) is a recognised quality metric and contributes to unnecessary antibiotic exposure.
Diagnosis
Your doctor will likely ask about your symptoms and request a urine sample. A dipstick test can detect signs of infection quickly, while a urine culture identifies the specific bacteria involved and guides antibiotic selection.
Symptom Assessment
Medical history & physical exam
Urinalysis
Dipstick + microscopy
Urine Culture
Identifies organism & sensitivity
Urinalysis Interpretation
- Leukocyte esterase: Sensitivity 75–96%; specificity 94–98%. Positive suggests pyuria (>5 WBC/hpf)
- Nitrites: Specificity ~95%; sensitivity ~50%. Only gram-negative Enterobacteriaceae reduce nitrates
- Combined LE + nitrite: Best discriminator in uncomplicated cystitis; negative dipstick has high NPV to exclude UTI
- Microscopy: Pyuria threshold: ≥10 WBC/mm³ on uncentrifuged specimen; bacteriuria: ≥10²–10⁵ CFU/mL depending on context
Imaging Indications
- Ultrasound: First-line for suspected obstruction, abscess, or paediatric UTI
- CT urogram: Diagnostic standard for pyelonephritis complications (abscess, emphysematous pyelonephritis), nephrolithiasis
- VCUG/MAG3: Evaluate vesico-ureteral reflux in paediatric recurrent UTI
- Cystoscopy: Recurrent haematuria, suspected bladder lesion, or structural abnormality
Trattamento IVU: antibiotici, idratazione e gestione delle IVU ricorrenti
Most UTIs are effectively treated with a short course of oral antibiotics. It's important to complete the full course even if symptoms improve early. Your doctor will choose the antibiotic based on the bacteria identified and local resistance patterns.
Important: Never self-medicate
Using the wrong antibiotic or stopping treatment early contributes to antibiotic resistance and may not cure the infection. Always follow your doctor's prescription.
| UTI Type | First-Line (EAU/IDSA) | Duration | Notes |
|---|---|---|---|
| Uncomplicated Cystitis | Nitrofurantoin, Fosfomycin, Pivmecillinam | 3–5 days | Avoid fluoroquinolones as first-line; preserve for complicated UTI |
| Uncomplicated Pyelonephritis (mild) | Ciprofloxacin (if local resistance <10%) or TMP-SMX guided by cultures | 7–14 days | Culture before starting; adjust to sensitivity results |
| Complicated UTI / Hospitalised Pyelonephritis | IV ceftriaxone or piperacillin-tazobactam (initial empirical) | 10–14 days (step-down oral when appropriate) | Blood cultures; urology consult if obstruction suspected |
| CAUTI | Per local antibiogram; remove/replace catheter | 7 days (14 days if slow response) | Do not treat asymptomatic bacteriuria in catheterized patients |
| Recurrent UTI (prophylaxis) | Nitrofurantoin 50mg nocte or post-coital, D-mannose, intravaginal oestrogens (post-menopausal) | 3–6 months | Exclude anatomical cause first; review after 6 months |
💧 Hydration
Drinking plenty of water helps flush bacteria from the urinary tract. Aim for 1.5–2 litres daily, more during hot weather or fever.
🌿 Symptom Relief
Paracetamol or ibuprofen may help with discomfort. Some patients find urinary alkalinising agents (e.g. potassium citrate) soothing, though evidence is limited.
Prevention
Stay well hydrated
Adequate fluid intake dilutes urine and encourages frequent voiding, reducing bacterial colonisation time in the bladder.
Wipe front to back
This prevents transfer of gut bacteria from the anal area to the urethra — a simple but highly effective hygiene practice.
Urinate after sexual intercourse
Voiding after sex helps flush bacteria that may have been introduced into the urethra during sexual activity.
Avoid irritating products
Perfumed soaps, douches, and deodorant sprays near the genital area can disrupt natural flora and increase infection risk.
Cranberry products & D-Mannose
Some evidence supports the use of cranberry extract (PACs) and D-Mannose supplements in reducing recurrent UTIs by inhibiting bacterial adhesion to the urothelium.
Manage underlying conditions
Good glycaemic control in diabetes, prompt treatment of urinary obstruction, and minimising unnecessary catheterisation all reduce UTI risk significantly.
Clinical Insights & Current Guidelines
EAU 2024 Urological Infections Guidelines — Key Updates
- • Fluoroquinolones are no longer recommended as empirical first-line therapy for uncomplicated cystitis due to ecological collateral damage and resistance pressure.
- • Fosfomycin trometamol (3g single dose) remains a preferred option for uncomplicated cystitis with favourable resistance profile.
- • Post-procedural antibiotic prophylaxis (e.g. ureterorenoscopy, PCNL) is recommended only when pre-operative urine culture is positive or contamination risk is high.
- • Catheter-associated bacteriuria: treat only if symptomatic, pregnant, or prior to urological instrumentation.
Antimicrobial Stewardship Considerations
- • Reserve carbapenems for documented ESBL/carbapenem-susceptible organisms; meropenem for KPC/NDM-producing Enterobacteriaceae only if no alternative.
- • Urine cultures from catheterised patients frequently represent colonisation — clinical context is paramount.
- • Repeated quinolone exposure promotes fluoroquinolone-resistant E. coli and MRSA — consider resistance monitoring in high-risk populations.
Urological Device Considerations
Ureteral access sheaths (UAS), nephrostomy drainage catheters, and JJ stents all represent foreign body surfaces that predispose to biofilm formation. Continuous suction sheaths (e.g. Manawa FANS series) reduce intra-renal pressure build-up during ureteroscopy, potentially lowering pyelovenous backflow and infectious complications. Appropriate antibiotic prophylaxis before endourological procedures and timely removal of drainage devices remain the cornerstones of post-procedural UTI prevention.
Domande frequenti: Infezioni delle vie urinarie
Quali sono i principali sintomi di un'infezione delle vie urinarie?
I sintomi più comuni di una IVU bassa (cistite) includono bruciore o dolore alla minzione (disuria), bisogno urgente e frequente di urinare, urina torbida o maleodorante e pressione pelvica. La IVU alta (pielonefrite) causa sintomi aggiuntivi: febbre superiore a 38°C, brividi, dolore al fianco, nausea e vomito. La pielonefrite richiede attenzione medica immediata.
Come si tratta un'infezione delle vie urinarie?
La maggior parte delle IVU non complicate viene trattata con una breve terapia antibiotica orale di 3-5 giorni. Le attuali linee guida EAU raccomandano nitrofurantoina, fosfomicina o pivmecillinam come opzioni di prima linea. I fluorochinoloni dovrebbero essere evitati come prima scelta a causa di problemi di resistenza. Le IVU complicate o alte possono richiedere 7-14 giorni di trattamento, e la pielonefrite grave può necessitare di antibiotici IV e ospedalizzazione.
Cosa causa le infezioni urinarie ricorrenti?
Le IVU ricorrenti (3 o più episodi all'anno) sono più comuni nelle donne per fattori anatomici. Le cause comuni includono attività sessuale, menopausa, svuotamento incompleto della vescica, calcoli renali, stenosi ureterali e uso prolungato di catetere urinario. Il trattamento comprende affrontare la causa sottostante, antibiotici profilattici a basso dosaggio, integrazione di D-mannosio o estrogeni intravaginali nelle donne in postmenopausa.
Qual è la differenza tra cistite e pielonefrite?
La cistite è un'infezione della vescica (vie urinarie inferiori) che causa tipicamente disuria, urgenza e frequenza senza febbre. La pielonefrite è un'infezione renale (vie urinarie superiori) più grave — che si presenta con febbre, dolore al fianco, nausea e compromissione sistemica. La pielonefrite richiede un trattamento antibiotico tempestivo ed eventualmente l'ospedalizzazione, in particolare in donne in gravidanza, anziani o pazienti immunocompromessi.
Come si possono prevenire le infezioni urinarie?
Le principali strategie di prevenzione includono: mantenersi ben idratati (1,5-2 litri di acqua al giorno), urinare dopo i rapporti sessuali, pulirsi dall'avanti all'indietro dopo aver usato il bagno, evitare prodotti profumati vicino all'area genitale e gestire le condizioni sottostanti come il diabete o l'ostruzione urinaria. Gli estratti di mirtillo rosso (PAC) e gli integratori di D-mannosio hanno evidenze di riduzione delle recidive inibendo l'adesione batterica all'urotelio.